Dare Bioscience, Inc. (DARE) - 10-Q Summary
Business Context and Reporting Period
Company: Dare Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Dare Bioscience is a women's health biotech company focused on contraception, sexual health, and infectious disease. The company operates under a dual-path strategy: pursuing traditional FDA approval for clinical-stage candidates (e.g., Ovaprene) and earlier market access via Section 503B compounding (e.g., DARE to PLAY). Revenue is currently driven by research and development services provided to the Gates Foundation.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $187,546 | $340,001 |
| Cost of Revenues | $319,889 | $562,214 |
| Net Loss | $(2,982,773) | $(5,982,662) |
| Loss Per Share (Basic & Diluted) | $(0.20) | $(0.41) |
| Cash and Cash Equivalents (End of Period) | $12,617,594 | |
| Working Capital Deficit | ~$(236,457) | |
| Accumulated Deficit | $(194,671,566) | |
| Deferred Grant Funding Liability | $14,954,724 |
Note: The company reported a working capital deficit of approximately $0.2 million. Cash balances are heavily comprised of restricted grant funds.
Material Changes vs. Prior Period
- Revenue: Revenue increased significantly to $340,001 for the six months ended June 30, 2026, compared to $4,255 in the prior year period. This is primarily due to new research and development service agreements with the Gates Foundation.
- Net Loss: Net loss improved to $(5.98) million for the six months ended June 30, 2026, compared to $(8.39) million in the prior year period. This improvement was driven by a substantial decrease in reported Research and Development (R&D) expenses.
- R&D Expenses: Reported R&D expenses decreased by 76% to $902,428 (six months 2026) from $3.73 million (six months 2025). This reduction is largely attributable to an increase in "contra R&D expenses" (grant funding offsets) totaling $8.2 million, rather than a reduction in actual development activity.
- SG&A Expenses: Selling, General, and Administrative expenses increased slightly to $4.84 million (six months 2026) from $4.69 million (six months 2025), partially due to a $0.3 million non-cash write-down of deferred offering costs.
- Cash Position: Cash and cash equivalents decreased from $24.7 million at December 31, 2025, to $12.6 million at June 30, 2026, reflecting a net cash burn of approximately $12.3 million from operating activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern within the next 12 months due to recurring losses, negative cash flows, and a working capital deficit. Additional capital is required to fund operations.
- Nasdaq Delisting Risk: On July 13, 2026, the company received a delisting determination letter from Nasdaq for failing to meet the $2.5 million stockholders' equity requirement. A hearing is scheduled for late August 2026. Failure to regain compliance could result in immediate suspension of trading.
- Product Updates:
- Ovaprene: The FDA approved a protocol amendment to the Phase 3 study but cautioned that the modified design (removing the 250 completer requirement) may not generate sufficient safety data for approval. The company expects top-line data in 2027.
- DARE to PLAY: The company expects to begin recording revenue from sales of this Section 503B compounded product in the third quarter of 2026.
- Consumer Health: Launched "Flora Sync LF5" under the DARE to RESTORE brand in June 2026.
- Financing Activities: The company is conducting a Regulation A Offering (Series A Preferred Stock and warrants) and has an equity line with Lincoln Park Capital Fund. Net proceeds from these activities in the first half of 2026 were approximately $1.8 million.
Investor Verification Checklist
- Nasdaq Hearing Outcome: Verify the result of the late August 2026 hearing regarding the stockholders' equity deficiency and potential delisting.
- Grant Funding Sustainability: Confirm the status of NIH and Gates Foundation grants, particularly given the expiration and reauthorization of the SBIR program in 2026, and the reliance on these funds to offset R&D costs.
- Ovaprene Regulatory Path: Monitor FDA communications regarding the sufficiency of the amended Phase 3 study design and the potential need for additional data or subjects.
- Cash Runway: Assess the company's ability to fund operations into the fourth quarter of 2026 and the terms of any future capital raises required to avoid insolvency.
- Revenue Recognition: Verify the timing and magnitude of revenue recognition from the new Section 503B products (DARE to PLAY) and consumer health products (Flora Sync LF5) starting in Q3 2026.